Edition:
India

Hikma Raises FY Rev Foreast For Injectables Business


Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Hikma Pharmaceuticals PLC ::IN MENA, OUR BRANDED BUSINESS IS CONTINUING TO GROW STEADILY AND WE REMAIN ON TRACK TO MEET OUR FULL YEAR GUIDANCE.ARE RAISING OUR 2018 GUIDANCE AND NOW EXPECT INJECTABLES REVENUE TO BE IN RANGE OF $825 MILLION TO $850 MILLION.SEES CORE INJECTABLES OPERATING MARGIN FOR FY TO BE BETWEEN 39% AND 40%.